NE
NEXI.US Neximmune Inc
- Market cap
- USD 139.00
- P/E
- -
- P/B
- 0.00x
- ROE
- -1,174.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2024.
Is NEXI.US undervalued?
Graham numberThe Graham number of Neximmune Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Neximmune Inc fundamental analysis
No fundamental analysis for Neximmune Inc yet.
Neximmune Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Neximmune Inc
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials…
Full company profileNeximmune Inc financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
Neximmune Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.24M |
| Gross Profit | -205K | -436K | -619K | -870K | -1.50M | -1.02M | -381K |
| Operating Income | -13.2M | -20.9M | -27.9M | -53.3M | -63.1M | -29.2M | -12.5M |
| EBITDA | -13.0M | -20.4M | -27.6M | -49.1M | -61.5M | -28.2M | -10.6M |
| Net Income | -12.8M | -20.3M | -31.6M | -51.7M | 514M | -32.3M | -10.8M |
| EPS | -14 | -23 | -35 | -57 | 534 | -31 | -7.83 |
| Balance Sheet | |||||||
| Total Assets | 14.1M | 13.7M | 11.3M | 91.0M | 43.1M | 8.59M | 5.86M |
| Total Liabilities | 3.33M | 3.11M | 27.1M | 7.27M | 10.8M | 5.08M | 4.94M |
| Shareholders' Equity | 10.8M | 10.6M | -15.8M | 83.8M | 32.3M | 3.51M | 921K |
| Cash & Short-term Investments | 12.1M | 10.1M | 5.10M | 81.8M | 34.6M | 4.65M | 2.42M |
| Total Debt | 35.0M | 53.6M | 19.1M | - | 1.02M | 68.8K | - |
| Cash Flow | |||||||
| Operating Cash Flow | -11.1M | -19.4M | -26.4M | -45.8M | -51.2M | -31.4M | -8.98M |
| Capital Expenditure | 938K | 1.25M | 865K | 2.35M | 1.26M | 48.7K | 8.00 |
| Free Cash Flow | -12.1M | -20.7M | -27.3M | -48.1M | -52.4M | -31.5M | -8.98M |
| Ratios | |||||||
| ROE | -118.7% | -191.3% | - | -61.8% | 1,591.9% | -921.6% | -1,174.1% |
| ROA | -90.7% | -148.0% | -280.0% | -56.8% | 1,194.1% | -376.4% | -184.4% |
| Net Profit Margin | - | - | - | - | - | - | -254.8% |
| Debt to Equity | 3.24x | 5.05x | - | - | 0.03x | 0.02x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Neximmune Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 378K | 0.41 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:25 on Oct 19, 2023.
Who owns Neximmune Inc
Top funds holding NEXI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| SSgA U.S. Total Market Index Strategy | 46.00 | 0.00% | +43.75% | Jun 2024 |
Top institutions holding NEXI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Sabby Management LLC | 49.9K | 3.58% | -16.62% | Jun 2024 |
| Raymond James & Associates | 10.8K | 0.77% | 0.00% | Sep 2024 |
| JPMorgan Chase & Co | 4.00K | 0.29% | 0.00% | Jun 2024 |
| Comerica Bank | 3.26K | 0.23% | 0.00% | Jun 2024 |
| Tower Research Capital LLC | 2.12K | 0.15% | +34.24% | Jun 2024 |
| UBS Group AG | 638.00 | 0.05% | +63,700.00% | Jun 2024 |
| BNP Paribas Arbitrage, SA | 41.00 | 0.00% | 0.00% | Jun 2024 |
| Bank of America Corp | 7.00 | 0.00% | 0.00% | Jun 2024 |
| Royal Bank of Canada | 0.00 | 0.00% | -100.00% | Jun 2024 |
| Wells Fargo & Co | 0.00 | 0.00% | -100.00% | Jun 2024 |
| EPIQ Capital Group, LLC | 0.00 | 0.00% | -100.00% | Sep 2024 |
| Slate Path Capital LP | 0.00 | 0.00% | -100.00% | Sep 2024 |
| Vanguard Group Inc | 0.00 | 0.00% | -100.00% | Sep 2024 |
| PNC Financial Services Group Inc | 0.00 | 0.00% | -100.00% | Sep 2024 |
Neximmune Inc company profile
- Company name
- Neximmune Inc
- Ticker
- NEXI.US
- Exchange
- USA Stocks
- Listed since
- Feb 12, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Fiscal year end
- December
- Address
- 9119 Gaither Road, Gaithersburg, MD, United States, 20877
- Phone
- 301 825 9810
- Website
- neximmune.com
About Neximmune Inc
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It also provides NEXI-004 which is in preclinical stage for EBV related diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Neximmune Inc management
7- Mr. John Trainer M.B.A.Consultant · born 1974
- Ms. Karen HaslbeckHead of Human Resources
- Dr. Daniel P. Bednarik Ph.d.Senior Vice President of Molecular Engineering & Protein Design
- Dr. Robert Douglas Knight M.D.Chief Medical Officer · born 1951
- Mr. Chad RubinSenior Vice President of Corporate Affairs
- Dr. Jack A. Ragheb M.D., Ph.D.Senior Vice President of Translational Science
- Mr. Matthew SchillerHead of Business Development